Candel Therapeutics Q3 net loss $8.7M; cash $77.2M, runway into Q1 2024; UPenn CAR-T partnership

Candel Therapeutics, Inc.

2022-Q3 EPS reported -$0.48 revenue$94,000

Net loss $8.7M vs $16.2M in Q3 2021; improvement driven by non-cash warrant liability changes.
Cash and equivalents $77.2M as of Sep 30, 2022; expected to fund operations into Q1 2024.
R&D expenses $5.4M, G&A $3.5M; increases due to higher headcount, clinical studies, and public company costs.
European Commission granted orphan drug designation for CAN-2409 in glioma; phase 3 protocol submitted.
Partnered with UPenn Center for Cellular Immunotherapies to study viral immunotherapy + CAR-T in solid tumors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Candel Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $31,000, net income $8.7 million.

Period: the third quarter ended September 30, 2022
Revenue: $31,000
Net income: $8.7 million
Result: reported results

Exact text from the filing

Research and Development Service Revenue, related party: Research and Development Service Revenue, related party, for the third quarters ended September 30, 2022 and 2021 was $31,000. Research and Development Expenses: Research and development expenses were $5.4 million for the quarter ended September 30, 2022 compared to $5.3 million for the comparable

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Candel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024193

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.